236 related articles for article (PubMed ID: 18849167)
1. Chalcogenopyrylium dyes as inhibitors/modulators of P-glycoprotein in multidrug-resistant cells.
Sawada GA; Raub TJ; William Higgins J; Brennan NK; Moore TM; Tombline G; Detty MR
Bioorg Med Chem; 2008 Nov; 16(22):9745-56. PubMed ID: 18849167
[TBL] [Abstract][Full Text] [Related]
2. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.
Rautio J; Humphreys JE; Webster LO; Balakrishnan A; Keogh JP; Kunta JR; Serabjit-Singh CJ; Polli JW
Drug Metab Dispos; 2006 May; 34(5):786-92. PubMed ID: 16455806
[TBL] [Abstract][Full Text] [Related]
3. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
4. ATP occlusion by P-glycoprotein as a surrogate measure for drug coupling.
Tombline G; Holt JJ; Gannon MK; Donnelly DJ; Wetzel B; Sawada GA; Raub TJ; Detty MR
Biochemistry; 2008 Mar; 47(10):3294-307. PubMed ID: 18275155
[TBL] [Abstract][Full Text] [Related]
5. Rational use of in vitro P-glycoprotein assays in drug discovery.
Polli JW; Wring SA; Humphreys JE; Huang L; Morgan JB; Webster LO; Serabjit-Singh CS
J Pharmacol Exp Ther; 2001 Nov; 299(2):620-8. PubMed ID: 11602674
[TBL] [Abstract][Full Text] [Related]
6. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
Regev R; Katzir H; Yeheskely-Hayon D; Eytan GD
FEBS J; 2007 Dec; 274(23):6204-14. PubMed ID: 17986257
[TBL] [Abstract][Full Text] [Related]
7. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
[TBL] [Abstract][Full Text] [Related]
8. A cationic chalcogenoxanthylium photosensitizer effective in vitro in chemosensitive and multidrug-resistant cells.
Holt JJ; Gannon MK; Tombline G; McCarty TA; Page PM; Bright FV; Detty MR
Bioorg Med Chem; 2006 Dec; 14(24):8635-43. PubMed ID: 16945541
[TBL] [Abstract][Full Text] [Related]
9. Selective modulation of P-glycoprotein-mediated drug resistance.
Bebawy M; Morris MB; Roufogalis BD
Br J Cancer; 2001 Dec; 85(12):1998-2003. PubMed ID: 11747345
[TBL] [Abstract][Full Text] [Related]
10. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
[TBL] [Abstract][Full Text] [Related]
11. Analogues of tetramethylrosamine as transport molecules for and inhibitors of P-glycoprotein-mediated multidrug resistance.
Gibson SL; Hilf R; Donnelly DJ; Detty MR
Bioorg Med Chem; 2004 Sep; 12(17):4625-31. PubMed ID: 15358289
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport.
Evers R; Kool M; Smith AJ; van Deemter L; de Haas M; Borst P
Br J Cancer; 2000 Aug; 83(3):366-74. PubMed ID: 10917553
[TBL] [Abstract][Full Text] [Related]
14. Acridones circumvent P-glycoprotein-associated multidrug resistance (MDR) in cancer cells.
Gopinath VS; Thimmaiah P; Thimmaiah KN
Bioorg Med Chem; 2008 Jan; 16(1):474-87. PubMed ID: 17933543
[TBL] [Abstract][Full Text] [Related]
15. Potential role for human P-glycoprotein in the transport of lacosamide.
Zhang C; Chanteux H; Zuo Z; Kwan P; Baum L
Epilepsia; 2013 Jul; 54(7):1154-60. PubMed ID: 23551115
[TBL] [Abstract][Full Text] [Related]
16. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein.
Wang EJ; Casciano CN; Clement RP; Johnson WW
Drug Metab Dispos; 2000 May; 28(5):522-8. PubMed ID: 10772630
[TBL] [Abstract][Full Text] [Related]
17. (+/-)-3'-O, 4'-O-dicynnamoyl-cis-khellactone, a derivative of (+/-)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells.
Shen X; Chen G; Zhu G; Fong WF
Bioorg Med Chem; 2006 Nov; 14(21):7138-45. PubMed ID: 16875827
[TBL] [Abstract][Full Text] [Related]
18. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux.
Hayeshi R; Masimirembwa C; Mukanganyama S; Ungell AL
Eur J Pharm Sci; 2006 Sep; 29(1):70-81. PubMed ID: 16846720
[TBL] [Abstract][Full Text] [Related]
19. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana.
Zhu HJ; Wang JS; Markowitz JS; Donovan JL; Gibson BB; Gefroh HA; Devane CL
J Pharmacol Exp Ther; 2006 May; 317(2):850-7. PubMed ID: 16439618
[TBL] [Abstract][Full Text] [Related]
20. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
Feng B; Mills JB; Davidson RE; Mireles RJ; Janiszewski JS; Troutman MD; de Morais SM
Drug Metab Dispos; 2008 Feb; 36(2):268-75. PubMed ID: 17962372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
